Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
Journal of Clinical Oncology · 10.05.2025 · 43 (14) · 1638-1649
DOI: 10.1200/jco-24-01283 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.05.2025. Verfasst von Daniel P Petrylak und 25 weiteren Autor:innen. Beteiligte Einrichtung: Yale Cancer Center, New Haven, CT. Hauptthemen laut MEDLINE: Docetaxel, Prostatic Neoplasms, Castration-Resistant, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE The standard of care for metastatic castration-resistant prostate cancer (mCRPC) after second-generation androgen receptor pathway inhibitor (ARPI) therapy is still docetaxel. The randomized, double-blind, phase III KEYNOTE-921 trial (Clinicaltrials.gov identifier: NCT03834506 ) evaluated the efficacy and safety of pembrolizumab or placebo plus docetaxel for previously treated mCRPC. METHODS Adults with mCRPC who progressed after androgen-deprivation therapy and one ARPI were randomly assigned 1:1 to pembrolizumab or placebo plus docetaxel with concomitant prednisone. Dual primary end points were radiographic progression-free survival (rPFS) by blinded independent central review per Prostate Cancer Working Group 3–modified RECIST 1.1 and overall survival (OS). Safety was a secondary end point. RESULTS Between May 30, 2019, and June 17, 2021, 515 participants were randomly assigned to pembrolizumab plus docetaxel and 515 to placebo plus docetaxel. Median time from random assignment to data cutoff date (June 20, 2022) at final analysis (FA) was 22.7 months (range, 12.1-36.7). At first interim analysis (data cutoff date: September 27, 2021), median rPFS was 8.6 months (95% CI, 8.3 to 10.2) with pembrolizumab plus docetaxel versus 8.3 months (95% CI, 8.2 to 8.5) with placebo plus docetaxel (hazard ratio [HR], 0.85 [95% CI, 0.71 to 1.01]; P = .03). At FA, median OS was 19.6 months (95% CI, 18.2 to 20.9) versus 19.0 months (95% CI, 17.9 to 20.9), respectively (HR, 0.92 [95% CI, 0.78 to 1.09]; P = .17). Grade ≥3 treatment-related adverse events occurred in 43.2% of participants who received pembrolizumab plus docetaxel and 36.6% of participants who received placebo plus docetaxel. Two and seven participants, respectively, died due to a treatment-related adverse event. Pneumonitis was the most common immune-mediated adverse event (7.0% v 3.1%). CONCLUSION The addition of pembrolizumab to docetaxel did not significantly improve efficacy outcomes for participants with previously treated mCRPC. The current standard of care remains unchanged.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Yale Cancer Center, New Haven, CT.
- Hopital Foch, Suresnes, France.
- National Cancer Center Hospital East, Chiba, Japan.
- Hospital Britanico de Buenos Aires, Buenos Aires, Argentina.
- Russian Scientific Center of Roentgenoradiology, Moscow, Russia.
- Institut Claudius Regaud IUCT Oncopole, Toulouse, France.
ORCID-Profile: Daniel P Petrylak, Nobuaki Matsubara, Rustem Gafanov, Howard Gurney, Andries M Bergman, Andrew J Armstrong, Russell Pachynski, Ray McDermott, Sergio Bracarda, Ray Manneh, Charles Schloss, Christian H Poehlein, Karim Fizazi
Zitieren
APA
Petrylak, D. P., Ratta, R., Matsubara, N., Korbenfeld, E., Gafanov, R., Mourey, L., Todenhöfer, T., Gurney, H., Kramer, G., Bergman, A. M., Zalewski, P., De Santis, M., Armstrong, A. J., Gerritsen, W., Pachynski, R., Byun, S. S., Retz, M., Levesque, E., McDermott, R., …, & Fizazi, K. (2025). Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. Journal of Clinical Oncology, 43(14), 1638-1649. https://doi.org/10.1200/jco-24-01283
Vancouver
Petrylak DP, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, et al. Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. Journal of Clinical Oncology. 2025;43(14):1638-1649. doi:10.1200/jco-24-01283
BibTeX
@article{Petrylak2025,
author = {Petrylak, Daniel P and Ratta, Raffaele and Matsubara, Nobuaki and Korbenfeld, Ernesto and Gafanov, Rustem and Mourey, Loic and Todenhöfer, Tilman and Gurney, Howard and Kramer, Gero and Bergman, Andries M and Zalewski, Pawel and De Santis, Maria and Armstrong, Andrew J and Gerritsen, Winald and Pachynski, Russell and Byun, Seok Soo and Retz, Margitta and Levesque, Eric and McDermott, Ray and Bracarda, Sergio and Manneh, Ray and Levartovsky, Meital and Li, Xin Tong and Schloss, Charles and Poehlein, Christian H and Fizazi, Karim},
title = {Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {14},
pages = {1638--1649},
doi = {10.1200/jco-24-01283}
}
EUVIMED